PRM160 - IMPACT OF POST-PROGRESSION OLARATUMAB (OLARA) MONOTHERAPY FOLLOWING DOXORUBICIN (DOX) MONOTHERAPY ON OVERALL SURVIVAL (OS).
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.2280
https://www.valueinhealthjournal.com/article/S1098-3015(18)35582-7/fulltext
Section Title :
Section Order :
1634
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35582-7&doi=10.1016/j.jval.2018.09.2280